secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K/A
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001628280-24-025241
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vanda board rejects conditional resignation of director Chrousos after less-than-majority vote
--------------------------------------------------------------------------------

- Director Phaedra S. Chrousos received less than majority votes at 2024 annual meeting, tendered conditional resignation.
- Board (excluding Chrousos) unanimously voted May 22, 2024 to reject resignation, citing qualifications and proxy advisory firm's recommendation related to Rights Agreement.
- Chrousos will continue as director until Vanda's 2027 annual meeting or until successor elected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024025241/0001628280-24-025241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024025241/vnda-20240517.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-025241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer